| Literature DB >> 33562649 |
Mingyue Chen1, Yashuang Dai1, Siyu Liu1, Yuxin Fan1, Zongxian Ding1, Dan Li1.
Abstract
Autophagy is a critical regulator of cellular survival, differentiation, development, and homeostasis, dysregulation of which is associated with diverse diseases including cancer and neurodegenerative diseases. Transcription factor EB (TFEB), a master transcriptional regulator of autophagy and lysosome, can enhance autophagic and lysosomal biogenesis and function. TFEB has attracted a lot of attention owing to its ability to induce the intracellular clearance of pathogenic factors in a variety of disease models, suggesting that novel therapeutic strategies could be based on the modulation of TFEB activity. Therefore, TFEB agonists are a promising strategy to ameliorate diseases implicated with autophagy dysfunction. Recently, several TFEB agonists have been identified and preclinical or clinical trials are applied. In this review, we present an overview of the latest research on TFEB biology and TFEB agonists.Entities:
Keywords: TFEB agonists; autophagy; lysosome; rapamycin; resveratrol
Year: 2021 PMID: 33562649 PMCID: PMC7914707 DOI: 10.3390/cells10020333
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600